Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1983 1
1984 1
1987 5
1988 1
1989 1
1990 2
1991 3
1992 8
1993 2
1994 3
1995 7
1996 4
1997 8
1998 7
1999 12
2000 11
2001 10
2002 17
2003 16
2004 16
2005 11
2006 15
2007 18
2008 22
2009 26
2010 18
2011 18
2012 17
2013 15
2014 11
2015 17
2016 12
2017 15
2018 15
2019 12
2020 12
2021 18
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

378 results
Results by year
Filters applied: . Clear all
Page 1
Antibody-Drug Conjugates: The Last Decade.
Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Joubert N, et al. Among authors: dumontet c. Pharmaceuticals (Basel). 2020 Sep 14;13(9):245. doi: 10.3390/ph13090245. Pharmaceuticals (Basel). 2020. PMID: 32937862 Free PMC article. Review.
Engineering therapeutic bispecific antibodies using CrossMab technology.
Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Klein C, et al. Among authors: dumontet c. Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16. Methods. 2019. PMID: 30453028 Free article. Review.
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, Johnson SK, Wardell CP, Thanendrarajan S, Zangari M, Facon T, Dumontet C, Barlogie B, Arbini A, Rustad EH, Maura F, Landgren O, Zhan F, van Rhee F, Schinke C, Davies FE, Morgan GJ, Walker BA. Boyle EM, et al. Among authors: dumontet c. Nat Commun. 2021 Jan 12;12(1):293. doi: 10.1038/s41467-020-20524-2. Nat Commun. 2021. PMID: 33436579 Free PMC article.
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Attal M, et al. Among authors: dumontet c. N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138. N Engl J Med. 2012. PMID: 22571202 Free article. Clinical Trial.
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C. Decaup E, et al. Among authors: dumontet c. Front Immunol. 2019 Aug 14;10:1943. doi: 10.3389/fimmu.2019.01943. eCollection 2019. Front Immunol. 2019. PMID: 31475004 Free PMC article.
[Antitubulin agents].
Dumontet C. Dumontet C. Bull Cancer. 2011 Nov;98(11):1275-85. doi: 10.1684/bdc.2011.1469. Bull Cancer. 2011. PMID: 22023745 Free article. Review. French.
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V. Deckert J, et al. Among authors: dumontet c. Clin Cancer Res. 2014 Sep 1;20(17):4574-83. doi: 10.1158/1078-0432.CCR-14-0695. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987056 Free article.
The druggability of intracellular nucleotide-degrading enzymes.
Rampazzo C, Tozzi MG, Dumontet C, Jordheim LP. Rampazzo C, et al. Among authors: dumontet c. Cancer Chemother Pharmacol. 2016 May;77(5):883-93. doi: 10.1007/s00280-015-2921-6. Epub 2015 Nov 27. Cancer Chemother Pharmacol. 2016. PMID: 26614508 Review.
378 results